← All organizations
Highest phase reached
Phase 3
First clinical trial
Jun 1, 2001Last known activity
Apr 5, 2018
Timeline
1990s
- Jan 1, 1997
Valerio— Founded
2010s
- Jun 1, 2016
DNA Therapeutics— Acquired
Drugs by trial phase (18 distinct, 28 trials)
Phase 3 (5 own, 0 via acquisition)
Phase 2 (8 own, 0 via acquisition)
Phase 1 (4 own, 1 via acquisition)
Indications
Studied for
- Candidiasis
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Fallopian Tube Neoplasms
- Herpes Labialis
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Lung Neoplasms
- Lymphoma
- Lymphoma, Non-Hodgkin
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Cutaneous
- Lymphoma, T-Cell, Peripheral
- Melanoma
- Mucositis
- Multiple Myeloma
- Neoplasms
- Neoplasms, Plasma Cell
- Neoplasms, Unknown Primary
- Ovarian Neoplasms
- Sarcoma
- Stomatitis
- Urinary Bladder Neoplasms
Subsidiaries (1 direct, 1 total across the full acquisition tree)
Recent trials (38)
- NCT03579628Lead sponsorPhase 1Apr 5, 2018
- NCT02548806Lead sponsorPhase 1Sep 1, 2015
- NCT01655693Lead sponsorPhase 3Jun 1, 2012
- NCT01764009Study directorPhase 1/Phase 2Jun 1, 2012
- NCT01764009Lead sponsorPhase 1/Phase 2Jun 1, 2012
- NCT01188707CollaboratorPhase 1/Phase 2Dec 1, 2010
- NCT01317927CollaboratorPhase 1Dec 1, 2010
- NCT01310244CollaboratorPhase 1/Phase 2Dec 1, 2010
- NCT01045915Lead sponsorPhase 1Jul 1, 2010
- NCT01045915Study directorPhase 1Jul 1, 2010
- NCT01385748Study directorPhase 2Apr 1, 2010
- NCT01385748Lead sponsorPhase 2Apr 1, 2010
- NCT00873119Study directorPhase 2Feb 1, 2009
- NCT00873119Lead sponsorPhase 2Feb 1, 2009
- NCT00865969CollaboratorPhase 2Dec 1, 2008
Details
- Founded
- Paris, FR Jan 1, 1997
- Last known activity
- Apr 5, 2018
Notes
--- Notes from BioAlliance Pharma: Acquired by Onxeo in 2014 --- --- Pre-folding founded info: 2014-07-01 Paris None France https://www.crunchbase.com/organization/onxeo#section-overview ---